Patents Assigned to High Point Pharmaceuticals, LLC
-
Patent number: 8946259Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.Type: GrantFiled: October 28, 2013Date of Patent: February 3, 2015Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, David Robert Jones, Devi Reddy Gohimukkula, Guoxiang Huang, Jeff Jiqun Zhu, Mohan Rao, Robert Carl Andrews, Tan Ren
-
Patent number: 8927549Abstract: Embodiments of the present invention provide adamantyl benzamide derivatives and pharmaceutical compositions comprising adamantyl benzamide derivatives. Methods of use of such compounds and compositions to modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) in a subject are also provided.Type: GrantFiled: November 17, 2009Date of Patent: January 6, 2015Assignee: High Point Pharmaceuticals, LLCInventors: Dharma Rao Polisetti, Suparna Gupta, Soren Ebdrup
-
Patent number: 8907096Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: GrantFiled: July 2, 2014Date of Patent: December 9, 2014Assignee: High Point Pharmaceuticals, LLCInventor: Soren Ebdrup
-
Patent number: 8853226Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.Type: GrantFiled: March 4, 2011Date of Patent: October 7, 2014Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
-
Patent number: 8846677Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.Type: GrantFiled: May 15, 2012Date of Patent: September 30, 2014Assignee: High Point Pharmaceuticals, LLCInventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
-
Patent number: 8809540Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: GrantFiled: January 11, 2013Date of Patent: August 19, 2014Assignee: High Point Pharmaceuticals, LLCInventor: Soren Ebdrup
-
Publication number: 20140200212Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.Type: ApplicationFiled: March 17, 2014Publication date: July 17, 2014Applicant: High Point Pharmaceuticals, LLCInventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
-
Patent number: 8772285Abstract: Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings, having histamine H3 antagonistic activity can be used in pharmaceutical compositions.Type: GrantFiled: October 25, 2012Date of Patent: July 8, 2014Assignee: High Point Pharmaceuticals, LLCInventors: Florencio Zaragoza Dorwald, Inge Thoger Christensen
-
Patent number: 8759535Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.Type: GrantFiled: February 16, 2011Date of Patent: June 24, 2014Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
-
Publication number: 20140066477Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.Type: ApplicationFiled: October 28, 2013Publication date: March 6, 2014Applicant: High Point Pharmaceuticals, LLCInventors: Adnan M.M. Mjalli, David Robert Jones, Devi Reddy Gohimukkula, Guoxiang Huang, Jeff Jiqun Zhu, Mohan Rao, Robert Carl Andrews, Tan Ren
-
Publication number: 20140024645Abstract: Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPAR? and may be useful for treating conditions mediated by the same.Type: ApplicationFiled: September 3, 2013Publication date: January 23, 2014Applicant: High Point Pharmaceuticals, LLCInventors: Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
-
Patent number: 8598353Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.Type: GrantFiled: November 19, 2010Date of Patent: December 3, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, David R. Jones, Devi Reddy Gohimukkula, Guoxiang Huang, Jeff J. Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
-
Patent number: 8563742Abstract: Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.Type: GrantFiled: August 25, 2009Date of Patent: October 22, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Bapu Gaddam, Robert C. Andrews, Samuel Victory, Suparna Gupta
-
Patent number: 8551993Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPAR? and should be useful for treating conditions mediated by the same.Type: GrantFiled: December 7, 2012Date of Patent: October 8, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
-
Publication number: 20130253007Abstract: The present invention provides methods of identifying compounds that selectively induce an oxidative stress response in a biological sample. The present invention further provides methods of treating a subject having a disease associated with oxidative stress using compounds that selectively induce an oxidative stress response in the subject. The invention further provides methods of selectively inducing an oxidative stress response in a cell.Type: ApplicationFiled: May 15, 2013Publication date: September 26, 2013Applicant: High Point Pharmaceuticals, LLCInventors: Jareer Nabeel Kassis, Otis Clinton Attucks, Matthew J. Kostura
-
Publication number: 20130231341Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: January 11, 2013Publication date: September 5, 2013Applicant: HIGH POINT PHARMACEUTICALS, LLCInventor: Soren Ebdrup
-
Patent number: 8513430Abstract: The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11?HSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11?HSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11?HSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable.Type: GrantFiled: July 25, 2011Date of Patent: August 20, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Dharma Rao Polisetti, Suparna Gupta
-
Patent number: 8501739Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.Type: GrantFiled: June 30, 2006Date of Patent: August 6, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
-
Patent number: 8450354Abstract: The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved.Type: GrantFiled: March 21, 2011Date of Patent: May 28, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Anitha Hari, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Mohan Rao, Raju Bore Gowda, Robert Carl Andrews, Rongyuan Xie, Soumya P. Sahoo, Tan Ren, William Kenneth Banner
-
Publication number: 20130102610Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPAR? and should be useful for treating conditions mediated by the same.Type: ApplicationFiled: December 7, 2012Publication date: April 25, 2013Applicant: HIGH POINT PHARMACEUTICALS, LLCInventor: High Point Pharmaceuticals, LLC